<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene S13I;W152C;L452R;D614G literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.S13I;W152C;L452R;D614G</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.<br/> (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_binding">Convalescent plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.<br/> (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Mean 2.7x reduction of NT50 value B.1.427 (Epsilon) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.<br/> (<a href="https://doi.org/10.1101/2021.09.06.459005" class="lit_link">Uriu et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Mean 2.3x reduction of NT50 value B.1.427 (Epsilon) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.<br/> (<a href="https://doi.org/10.1101/2021.09.06.459005" class="lit_link">Uriu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.<br/> (<a href="https://doi.org/10.1016/j.cell.2021.03.013" class="lit_link">Garcia-Beltran et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.<br/> (<a href="https://doi.org/10.1101/2021.05.13.444010" class="lit_link">Pegu et al (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.<br/> (<a href="https://doi.org/10.1101/2021.06.28.449914" class="lit_link">Choi et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> 6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.<br/> (<a href="https://doi.org/10.1101/2021.03.07.21252647" class="lit_link">Deng et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccinee_plasma_binding">Vaccinee plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.<br/> [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.<br/> (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
